Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin

Karina D. Valerius, Gregory K. Ogilvie, Martin J. Fettman, Judy A. Walton, Kristi Richardson, Barbara E. Powers, Elizabeth A. McNiel, Quinton Rogers

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective - To determine the effectiveness and safety of asparaginase administered SC versus IM for treatment of multicentric lymphoma in dogs receiving doxorubicin. Design - Prospective study. Animals - 49 dogs with multicentric lymphoma. Procedure - Dogs were treated with doxorubicin every 3 weeks, for a total of 5 treatments, and were given 3 weekly treatments of asparaginase, SC or IM. Using high-performance liquid chromatography, mean plasma asparagine, aspartic acid, glutamine, and glutamic acid concentrations were determined in dogs before and during treatment with asparaginase (10,000 U/m2 of body surface area, once a week for 3 weeks). Asparaginase was administered SC in 23 dogs and IM in 26 dogs. Variables evaluated included time to response to chemotherapy, remission and survival times, and clinical and serum biochemical indicators of toxicoses. Results - Using the World Health Organization's staging system for lymphoma, 30 dogs were in clinical stage III and 19 were in clinical stage IV. One week after asparaginase treatment, plasma asparagine concentrations were low and plasma aspartic acid, glutamine, and glutamic acid concentrations were high. Differences in plasma amino acid concentrations were not found between SC and IM groups. For dogs in clinical stage IV, IM administration of asparaginase significantly decreased the number of days to complete remission, compared with SC administration (8 vs 17 days, respectively). For dogs in clinical stage III, IM administration favorably increased the duration of first remission (191 vs 103 days) and survival time (289 vs 209 days). Overall, dogs treated IM had a faster response to chemotherapy (9 vs 15 days), a longer remission (191 vs 109 days), and a longer survival time (286 vs 198 days), compared with all dogs treated SC. Asparaginase toxicoses were not observed regardless of the route of administration. Clinical Implications - For dogs with multicentric lymphoma that are receiving doxorubicin, IM treatment with asparaginase is more effective that SC treatment.

Original languageEnglish (US)
Pages (from-to)353-356
Number of pages4
JournalJournal of the American Veterinary Medical Association
Volume214
Issue number3
StatePublished - Feb 1 1999

Fingerprint

asparaginase
Asparaginase
doxorubicin
lymphoma
Doxorubicin
Lymphoma
Dogs
dogs
remission
Therapeutics
Asparagine
asparagine
aspartic acid
Glutamine
glutamic acid
Aspartic Acid
glutamine
drug therapy
poisoning
Glutamic Acid

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin. / Valerius, Karina D.; Ogilvie, Gregory K.; Fettman, Martin J.; Walton, Judy A.; Richardson, Kristi; Powers, Barbara E.; McNiel, Elizabeth A.; Rogers, Quinton.

In: Journal of the American Veterinary Medical Association, Vol. 214, No. 3, 01.02.1999, p. 353-356.

Research output: Contribution to journalArticle

Valerius, Karina D. ; Ogilvie, Gregory K. ; Fettman, Martin J. ; Walton, Judy A. ; Richardson, Kristi ; Powers, Barbara E. ; McNiel, Elizabeth A. ; Rogers, Quinton. / Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin. In: Journal of the American Veterinary Medical Association. 1999 ; Vol. 214, No. 3. pp. 353-356.
@article{c5c59c6736fd4f42b257b21293d1919a,
title = "Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin",
abstract = "Objective - To determine the effectiveness and safety of asparaginase administered SC versus IM for treatment of multicentric lymphoma in dogs receiving doxorubicin. Design - Prospective study. Animals - 49 dogs with multicentric lymphoma. Procedure - Dogs were treated with doxorubicin every 3 weeks, for a total of 5 treatments, and were given 3 weekly treatments of asparaginase, SC or IM. Using high-performance liquid chromatography, mean plasma asparagine, aspartic acid, glutamine, and glutamic acid concentrations were determined in dogs before and during treatment with asparaginase (10,000 U/m2 of body surface area, once a week for 3 weeks). Asparaginase was administered SC in 23 dogs and IM in 26 dogs. Variables evaluated included time to response to chemotherapy, remission and survival times, and clinical and serum biochemical indicators of toxicoses. Results - Using the World Health Organization's staging system for lymphoma, 30 dogs were in clinical stage III and 19 were in clinical stage IV. One week after asparaginase treatment, plasma asparagine concentrations were low and plasma aspartic acid, glutamine, and glutamic acid concentrations were high. Differences in plasma amino acid concentrations were not found between SC and IM groups. For dogs in clinical stage IV, IM administration of asparaginase significantly decreased the number of days to complete remission, compared with SC administration (8 vs 17 days, respectively). For dogs in clinical stage III, IM administration favorably increased the duration of first remission (191 vs 103 days) and survival time (289 vs 209 days). Overall, dogs treated IM had a faster response to chemotherapy (9 vs 15 days), a longer remission (191 vs 109 days), and a longer survival time (286 vs 198 days), compared with all dogs treated SC. Asparaginase toxicoses were not observed regardless of the route of administration. Clinical Implications - For dogs with multicentric lymphoma that are receiving doxorubicin, IM treatment with asparaginase is more effective that SC treatment.",
author = "Valerius, {Karina D.} and Ogilvie, {Gregory K.} and Fettman, {Martin J.} and Walton, {Judy A.} and Kristi Richardson and Powers, {Barbara E.} and McNiel, {Elizabeth A.} and Quinton Rogers",
year = "1999",
month = "2",
day = "1",
language = "English (US)",
volume = "214",
pages = "353--356",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "3",

}

TY - JOUR

T1 - Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin

AU - Valerius, Karina D.

AU - Ogilvie, Gregory K.

AU - Fettman, Martin J.

AU - Walton, Judy A.

AU - Richardson, Kristi

AU - Powers, Barbara E.

AU - McNiel, Elizabeth A.

AU - Rogers, Quinton

PY - 1999/2/1

Y1 - 1999/2/1

N2 - Objective - To determine the effectiveness and safety of asparaginase administered SC versus IM for treatment of multicentric lymphoma in dogs receiving doxorubicin. Design - Prospective study. Animals - 49 dogs with multicentric lymphoma. Procedure - Dogs were treated with doxorubicin every 3 weeks, for a total of 5 treatments, and were given 3 weekly treatments of asparaginase, SC or IM. Using high-performance liquid chromatography, mean plasma asparagine, aspartic acid, glutamine, and glutamic acid concentrations were determined in dogs before and during treatment with asparaginase (10,000 U/m2 of body surface area, once a week for 3 weeks). Asparaginase was administered SC in 23 dogs and IM in 26 dogs. Variables evaluated included time to response to chemotherapy, remission and survival times, and clinical and serum biochemical indicators of toxicoses. Results - Using the World Health Organization's staging system for lymphoma, 30 dogs were in clinical stage III and 19 were in clinical stage IV. One week after asparaginase treatment, plasma asparagine concentrations were low and plasma aspartic acid, glutamine, and glutamic acid concentrations were high. Differences in plasma amino acid concentrations were not found between SC and IM groups. For dogs in clinical stage IV, IM administration of asparaginase significantly decreased the number of days to complete remission, compared with SC administration (8 vs 17 days, respectively). For dogs in clinical stage III, IM administration favorably increased the duration of first remission (191 vs 103 days) and survival time (289 vs 209 days). Overall, dogs treated IM had a faster response to chemotherapy (9 vs 15 days), a longer remission (191 vs 109 days), and a longer survival time (286 vs 198 days), compared with all dogs treated SC. Asparaginase toxicoses were not observed regardless of the route of administration. Clinical Implications - For dogs with multicentric lymphoma that are receiving doxorubicin, IM treatment with asparaginase is more effective that SC treatment.

AB - Objective - To determine the effectiveness and safety of asparaginase administered SC versus IM for treatment of multicentric lymphoma in dogs receiving doxorubicin. Design - Prospective study. Animals - 49 dogs with multicentric lymphoma. Procedure - Dogs were treated with doxorubicin every 3 weeks, for a total of 5 treatments, and were given 3 weekly treatments of asparaginase, SC or IM. Using high-performance liquid chromatography, mean plasma asparagine, aspartic acid, glutamine, and glutamic acid concentrations were determined in dogs before and during treatment with asparaginase (10,000 U/m2 of body surface area, once a week for 3 weeks). Asparaginase was administered SC in 23 dogs and IM in 26 dogs. Variables evaluated included time to response to chemotherapy, remission and survival times, and clinical and serum biochemical indicators of toxicoses. Results - Using the World Health Organization's staging system for lymphoma, 30 dogs were in clinical stage III and 19 were in clinical stage IV. One week after asparaginase treatment, plasma asparagine concentrations were low and plasma aspartic acid, glutamine, and glutamic acid concentrations were high. Differences in plasma amino acid concentrations were not found between SC and IM groups. For dogs in clinical stage IV, IM administration of asparaginase significantly decreased the number of days to complete remission, compared with SC administration (8 vs 17 days, respectively). For dogs in clinical stage III, IM administration favorably increased the duration of first remission (191 vs 103 days) and survival time (289 vs 209 days). Overall, dogs treated IM had a faster response to chemotherapy (9 vs 15 days), a longer remission (191 vs 109 days), and a longer survival time (286 vs 198 days), compared with all dogs treated SC. Asparaginase toxicoses were not observed regardless of the route of administration. Clinical Implications - For dogs with multicentric lymphoma that are receiving doxorubicin, IM treatment with asparaginase is more effective that SC treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032904084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032904084&partnerID=8YFLogxK

M3 - Article

VL - 214

SP - 353

EP - 356

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 3

ER -